# Yale chemist Craig Crews founded a biotechnology company in New Haven.

*biotech · news · 2026-05-08 · Medical Xpress*

## Key points

- Vepdegestrant (Veppanu) is the first PROTAC therapy approved by the FDA for breast cancer.
- Vepdegestrant is co-developed by Arvinas and Pfizer for estrogen receptor-positive, ESR1-mutated breast cancer.
- PROTACs, pioneered at Yale, are now positioned for development in diseases beyond cancer, including neurodegeneration.
- Crews’s earlier research led to Kyprolis, an FDA-approved proteasome inhibitor for multiple myeloma.

**Companies:** Pfizer, Johnson & Johnson, Arvinas
**Countries:** United States

[Read the full story on Medical Xpress](https://medicalxpress.com/news/2026-05-technology-fda-breast-cancer-treatment.html)

---

Canonical: https://newsio.io/n/4d075d42-3fa8-4a24-8c73-8ee1b08ebdeb/yale-chemist-craig-crews-founded-a-biotechnology-company-in-new-haven-his-compan
Summarized by Newsio from Medical Xpress. https://newsio.io/how-it-works